Akt and hippo pathways in Ewing's sarcoma tumors and their prognostic significance

Journal of Cancer

Volumn 6, Issue 10, 2015, Pages 1005-1010

  Ahmed, Atif A ^a   Abedalthagafi, Malak ^a   Anwar, Ahmed E ^b   Bui, Marilyn M ^c  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Akt; Biomarkers; Ewing's sarcoma; Immunohistochemistry; Tissue microarray

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE HIPPO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OVERALL SURVIVAL; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; YOUNG ADULT;

EID: 84947763111     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.12703     Document Type: Article

References (26)

1. Moore DD, Haydon RC. Ewing's sarcoma of bone. Cancer Treat Res. 2014; 162:93-115.
2. Thacker MM, Temple HT, Scully SP. Current treatment for Ewing's sarcoma. Expert rev anticancer ther. 2005; 5:319-31
3. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol. 2008; 20:412-8
4. Seddon BM, Whelan JS. Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma. Paediatr drugs. 2008; 10:93-105
5. Hotfilder M, Sondermann P, Senß A, et al. P13K/AKT is involved in mediating survival signals that rescue Ewing tumor cells from fibroblast growth factor 2-induced cell death. Br J Cancer. 2005; 92: 705-710
6. Chandhanayingyong C, Kim Y, Staples JR, et al. MAP/ERK signaling in osteosarcoma, Ewing sarcoma and chondrosarcomas: Therapeutic implications and future directions. Sarcoma. 2012; 2012: 404810
7. Cironi L, Riggi N, Provero P, et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One. 2008; 3: e2634
8. Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol. 2010; 11:105-6
9. Yamamoto T, Ohno T, Wakahara K, et al. Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma. J Cancer Res Clin Oncol. 2009; 135:1125-36
10. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene. 2003; 22:9282-7
11. Kilic-Eren M, Boylu T, Tabor V. Targeting PI3K/Akt represses Hypoxia inducible factor-1alpha activation and sensitizes rhabdomyosarcoma and Ewing's sarcoma cells for apoptosis. Cancer Cell Int. 2013; 13:36
12. Li J, You T, Jing J. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif. 2014; 47:152-60
13. Xia Y, Chang T, Wang Y, et al. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One. 2014; 9:e91770
14. Lamar JM, Stern P, Liu H, et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 2012; 109:E2441-50
15. Schlauder SM, Steffensen TS, Morgan M, et al. Assessment of muscarinic and nicotinic acetylcholine receptor expression in primitive neuroectodermal tumor/Ewing family of tumor and desmoplastic small round cell tumor: an immunohistochemical and Western blot study of tissue microarray and cell lines. Fetal Pediatr Pathol. 2008; 27:83-97
16. Scotlandi K, Manara MC, Serra M, et al. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer. 2011; 47:1258-66
17. Saini KS, Loi S, de Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013; 39:935-46
18. Mora J, Rodríguez E, de Torres C, et al. Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. Pediatr Blood Cancer. 2012; 58:532-8
19. van de Luijtgaarden AC, Versleijen-Jonkers YM, Roeffen MH, et al. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients. Target Oncol. 2013; 8:253-60
20. Li XJ, Leem SH, Park MH, et al. Regulation of YAP through an Akt-dependent process by 3, 3'-diindolylmethane in human colon cancer cells. Int J Oncol. 2013; 43:1992-8
21. Hsu JH, Lawlor ER. BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma. Oncogene. 2011; 30:2077-85
22. Douglas D, Hsu JH, Hung L, et al. BMI-1 promotes Ewing's sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 2008; 68: 6507-15
23. Wang H, Du YC, Zhou XJ, et al. The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy. Cancer Metastasis Rev. 2014; 33:173-81
24. Silvany RE, Eliazer S, Wolff NC, et al. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene. 2000; 19:4523-30.
25. Chappell WH, Steelman LS, Long JM, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011; 2:135-64.
26. Stegeman H, Span PN, Kaanders JH, et al. Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treat Rev. 2014; 40:1182-1191.